BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Summary

This is a multi-center, open-label, Phase I/II clinical study of BPB-101 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of BPB-101.

Timeline

Start

2023-05-16

Primary completion

2025-08-02

Completion

2025-09-01

Drugs

Indications